Home AstaReal® Astaxanthin Products Why AstaReal® Distributors About Us AstaReal Group Subsidiary - AstaVita, Inc., Releases Intermin Results of Sarcopenia Clinical Study AstaMed® MYO, Prescription Medical Food for Clinical Dietary Management of Sarcopenia, Meets Primary One Month Objective of Increased Muscle Strength in Two Phase Study The New Formulation From Astavita Containing Proprietary Natural Astaxanthin Significantly Improved Muscle Strength in a Randomized, Double-Blind, Placebo-Controlled Clinical Study at the University of Washington BELLEVUE, WA--(Sep 8, 2016) - Astavita, Inc., a WA-based provider of nutraceutical products containing proprietary natural astaxanthin and a global brand of AstaReal Group, today announced the interim results of a clinical study showing patients with sarcopenia significantly improved muscle strength as a result of receiving 30 days of a natural astaxanthin formulation without any lifestyle modifications or additional exercise protocols. The ongoing study is designed to explore the effectiveness of AstaMed MYO among sarcopenia adult patients who have impaired muscle function. Final results are anticipated in Q4' 2016 or Q1' 2017. The official launch of AstaMed MYO is scheduled for Q4' 2016 and will be available from pharmacies. During this interim period, patients demonstrated statistically significant double digit improvements in muscle strength (maximal voluntary contractions of leg muscles) as a preliminary result of daily administration of AstaMed MYO. It is believed that oxidative stress lowered by AstaMed MYO's astaxanthin formulation allowed the subjects to generate greater force in skeletal muscles through improved muscle metabolism. "Astavita is continuing to pioneer the clinical development of astaxanthin-based products to address unmet nutritional and health needs for individuals, such as those living with sarcopenia," said Dan Henry, General Manager, Astavita, Inc. "We're aggressively expanding our research and development capabilities to provide new and innovative solutions for the 21st century. There is an increasing need for new options to help address the long term health requirements of people living with the debilitating effects of sarcopenia and associated loss of muscle function and performance. These interim results support the effectiveness of AstaMed MYO as a new clinical strategy for sarcopenia patients." The interim results represent the first marker of a 4-month study being conducted at the University of Washington among more than 50 male and female adult subjects, aged 65-85 years of age, with evidence of skeletal muscle mitochondrial dysfunction. The second and final marker will represent an additional 3-month period in which participants receiving AstaMed MYO, combined with exercise training, will be evaluated. About Sarcopenia Sarcopenia is the degenerative loss of skeletal muscle. In sarcopenia, muscle mass, quality, and strength progressively decreases beyond the normal aging process, compromising physical function and independence, increasing risk of disability, and lowering quality of life in older adults. Although it is estimated that sarcopenia affects approximately 45% of the U.S. senior population and exceeds $18 billion dollars in direct healthcare costs, there are no approved pharmaceutical drugs for the treatment of sarcopenia. Beginning October 2016, sarcopenia will be coded in the International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) under the code of M62.84 About AstaMed® MYO AstaMed MYO is a prescription medical food for the clinical dietary management of sarcopenia. The formulation consists of proprietary natural astaxanthin as well as natural tocotrienols, zinc and vitamin D3. The product is expected to be available in Q4' 2016 from pharmacies. For more information, please visit www.astamed.net About AstaMed and Astavita, Inc. AstaMed is the medical food brand of Astavita, Inc., a health-focused company specializing in the development and marketing of nutraceutical products containing proprietary natural astaxanthin. Astavita is a member of the AstaReal Group, a fully owned subsidiary of Fuji Chemical Group and global pioneers in natural astaxanthin cultivation, R&D and clinical science. For more information, please visit www.astavita.com More news Visit AstaReal at Vitafoods Europe Wednesday, April 12, 2017 - Vitafoods Europe is the annual event where the entire nutraceutical supply chain does business, attracting 18,500+ of the most senior decision-makers in the global nutraceutical industry. Fight Fatigue Naturally with AstaReal® Thursday, November 17, 2016 - A new study published in the Journal of Clinical Therapeutics & Medicines has demonstrated that AstaReal® astaxanthin was simultaneously effective against both mental and physical fatigue. AstaReal Congratulates Karin Lundqvist, Swedish National Volleyball Player & AstaReal® Brand Ambassador, on a Fantastic Career! Wednesday, September 28, 2016 - Karin Lundqvist is one of the biggest profiles in Swedish Volleyball. After an incredibly successful 21 years as an elite player in both volleyball and beach volleyball, she has chosen to retire from the professional circuit. AstaReal Group Subsidiary - AstaVita, Inc., Releases Intermin Results of Sarcopenia Clinical Study Wednesday, September 28, 2016 - AstaMed® MYO, Prescription Medical Food for Clinical Dietary Management of Sarcopenia, Meets Primary One Month Objective of Increased Muscle Strength in Two Phase Study AstaReal to showcase their product range and hold 2 presentations in Vitafoods Europe 2016 Wednesday, May 4, 2016 - Visit AstaReal during Vitafoods Europe at stand i29, to learn more about natural astaxanthin and its incredible benefits for human health. Visitors will have the opportunity to discover more about AstaReal´s superior product range and natural astaxanthin´s unlimited potential as a healthy aging ingredient. You will also have the opportunity meet with our expert staff who will be attending. AstaReal to Host Exclusive Healthy Aging Webinar Monday, April 4, 2016 - Register Now! Join AstaReal, the pioneer of the natural astaxanthin industry, and discover the science behind this amazing molecule, why it is so good for you and explore its unlimited potential as a healthy aging ingredient. Start your "Preemptive Medicine with Natural Astaxanthin" Wednesday, January 20, 2016 - The AstaReal® International Symposium will be held on the 13th of February 2016 in Tokyo, Japan. Entitled ”Start Your ”Preemptive Medicine” with Natural Astaxanthin!” the event will bring together experts from around the world to share the latest in natural astaxanthin research. Washington State Governor Jay Inslee, Leads Trade Mission Visit to Fuji Chemical Industries Co., Ltd.’s AstaReal Headquarters in Tokyo Monday, September 14, 2015 - In May 2014, Fuji Chemical Industries opened a 59,000 sq. ft. factory in Moses Lake, Washington to meet the growing global demand for natural astaxanthin. At an investment of 34 million USD, the Moses Lake facility became the company’s second production base for natural algae astaxanthin, utilizing the same unique cultivation technology developed in the original factory in Sweden. New study shows "natural astaxanthin may reduce muscle damage in soccer players" Tuesday, August 11, 2015 - In a recent double blind placebo study, Ivana Baralic - of the sports medicine association of Serbia- and her team investigated the anti-inflammatory and antioxidant effects of astaxanthin. The results showed improvement in immune response and reduced muscle inflammation. AstaReal to Present on the Clinical Evidence of Natural Astaxanthin Supplementation on Brain Health Tuesday, July 21, 2015 - AstaReal´s Chief Scientific Liaison, Dr. Marco Narducci, has been invited to present at Food Matters Live in London on the 17th of November. Do not miss this opportunity to learn more about one of the hottest topics in the nutraceutical market today; Healthy Aging. Tuesday, March 31, 2015 - Mr. Mahmoud Farag from AstaReal Sweden AB, will be giving valuable insights on the topic of healthy aging and how science has shown that natural astaxanthin could be the ultimate healthy aging nutraceutical. Outstanding performance for the Swedish Ski Team in the World cup Monday, March 2, 2015 - As a proud sponsor of the Swedish Ski Team, we would like to congratulate the Team on their excellent performance at the World cup event that took place in Falun, Sweden AstaREAL® For Heart Health Tuesday, January 27, 2015 - Our colleague Janice Brown of AstaReal Inc., explains why AstaREAL® astaxanthin is set to become one of the ‘go to’ heart health ingredients that consumers reach for without hesitation. AstaReal, Inc. Announces its Successful Canadian Product License Approval for Astaxanthin of up to 12mg per day Friday, August 1, 2014 - Fantastic news for AstaReal, Inc. and the Canadian market, who will benefit from AstaREAL® natural astaxanthin products. Read the full press release here. Press Release - EFSA Novel Food Ingredient (NFI) Opinion on AstaREAL® Friday, July 25, 2014 - Last week, the EFSA panel on Dietetic Products, Nutrition and Allergies (NDA) published a scientific opinion on the proposed use of 4 mg algal astaxanthin in dairy products and fruit drinks. Read our response to the opinion here. AstaReal Triples its Production Capacity of Natural Astaxanthin to Meet Increased Demand. Thursday, May 15, 2014 - AstaReal Technology opened its new manufacturing facility in Moses Lake on May 14th with a grand celebration attended by Washington State Governor Jay Inslee and community leaders from Grant County and the City of Moses Lake. The new 59.000 sq.ft plant is to be in full operation in July 2014 and will initially employ 45 people. Vitafoods Europe 2014 Monday, March 31, 2014 - AstaReal will exhibit again this year at Vitafoods Europe. We will be at stand 19045. More Gold for Sweden's Cross Country Ski Team Monday, February 17, 2014 - Sweden on Sunday took another gold with a dominant performance in the Men's 4x10km cross country relay, completing a rare and famous double after also winning the women's event. Keep in touch Please choose your country Choose country Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Antarctic Territory British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Canton and Enderbury Islands Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos [Keeling] Islands Colombia Comoros Congo - Brazzaville Congo - Kinshasa Cook Islands Costa Rica Croatia Cuba Cyprus Czech Republic Côte d’Ivoire Denmark Djibouti Dominica Dominican Republic Dronning Maud Land Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories French Southern and Antarctic Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Honduras Hong Kong SAR China Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Johnston Island Jordan Kazakhstan Kenya Kiribati Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macau SAR China Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Metropolitan France Mexico Micronesia Midway Islands Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar [Burma] Namibia Nauru Nepal Netherlands Netherlands Antilles Neutral Zone New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Vietnam Northern Mariana Islands Norway Oman Pacific Islands Trust Territory Pakistan Palau Palestinian Territories Panama Panama Canal Zone Papua New Guinea Paraguay People's Democratic Republic of Yemen Peru Philippines Pitcairn Islands Poland Portugal Puerto Rico Qatar Romania Russia Rwanda Réunion Saint Barthélemy Saint Helena Saint Kitts and Nevis Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Saudi Arabia Senegal Serbia Serbia and Montenegro Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Korea Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria São Tomé and Príncipe Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu U.S. Minor Outlying Islands U.S. Miscellaneous Pacific Islands U.S. Virgin Islands Uganda Ukraine Union of Soviet Socialist Republics United Arab Emirates United Kingdom United States Unknown or Invalid Region Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Wake Island Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Åland Islands Choose category Choose category General enquiry Bulk products Retail products Animal products I want to be a distributor Where can I find AstaREAL® products Name E-mail Message Our Head Office AstaReal AB Forumvägen 14, Level 16 131 53 Nacka SWEDEN Sign up for our newsletters Copyright 2014 AstaReal AB All rights reserved / We use cookies